Associate Director, Quality Control
Rezolute Bio
Associate Director, Quality Control
Rezolute Bio
Develops monoclonal antibodies for rare diseases
Develops monoclonal antibodies for rare diseases
Rezolute Bio develops therapies for rare diseases, led by RZ358 for congenital hyperinsulinism and RZ402 for diabetic macular edema. RZ358 is a human monoclonal antibody that binds insulin to reduce its activity, aiming to lessen hypoglycemia, while RZ402 is an oral plasma kallikrein inhibitor for DME. The company differentiates itself by targeting rare, unmet-need conditions and pursuing late-stage candidates in both antibody and small-molecule formats. Its goal is to bring approved therapies to patients by advancing its programs through development to commercialization.
Explore more opportunities at Rezolute Bio